This is a past event. Registration is closed. View other AmCham Shanghai events.
Kenneth Jarrett
President at The American Chamber of Commerce in ShanghaiKenneth Jarrett has been President of the American Chamber of Commerce in Shanghai since September 2013. Prior to that he was the Greater China Chairman for APCO Worldwide, a Washington-based public affairs consultancy from 2008 to 2013, and before that a U.S. diplomat from 1982 to 2008. During his 26-year diplomatic career, his postings included Consul General in Shanghai, Deputy Consul General in Hong Kong, and Director of Asian Affairs at the White House National Security Council. He also served in Beijing, Chengdu, Singapore, and had several assignments in Washington, DC. Mr. Jarrett has degrees from Cornell University, Yale University and the National War College.
Chunlin Jin
Director of Shanghai Health Development Research CenterMr. Chunlin Jin currently holds various roles including:
• Director of Shanghai Health Development Research Center
• Vice President and Secretary General of Shanghai Health Economics Association
• Vice Chairman and Secretary General of Shanghai Health System Logistics Management Association
• Vice President of the Professional Committee of Health Management Statistics in Chinese Health Information Association
• Executive Director of the 8th China National Health Economics Association
• Standing Committee Member of Professional Committee of Health Finance and Policy in Chinese Health Economics Association
• Expert Group of Comprehensive Healthcare Reform Joint Conference of Shanghai, Jiangsu, Zhejiang, Anhui and Fujian Provinces
• Deputy Editor-in-chief of the Journal of Chinese Health Resources
• Chairman of the 1st Academic Committee of Health Economics Research
• Consultant of Liberation Daily in Health Area
Previously, Mr. Chunlin Jin was the Deputy Director of the Planning and Finance Division of Shanghai Municipal Health Bureau. His main area of research is health economics and hospital management.
Howard Chen
Principal at IQVIAHoward has more than 15 years of management consulting and investment & banking experiences in healthcare industries in the US, APAC region and China. His extensive experiences include cross-border M&A deals and fund raising for various healthcare players including investment funds, bio-pharmas, and medical technology players. He also has significant experience in corporate strategy, M&A strategy, portfolio strategy, brand strategy, new product launch, market access strategy, for pharmaceutical and medical technology products. Howard previously worked in the private equity and venture capital funds under Singapore’s sovereign wealth fund, Temasek.
Anita Wei
Director, Public Affairs & Communications, Greater China of BDAnita Wei is the Senior Director of Public Affairs & Communications for BD Greater China. She joined BD in late 2011 and is a member of the BD Greater China Leadership Team as well as the China Operation Committee. In this role, Anita is responsible for developing and managing BDX China level strategic programs focusing on HCW and patient safety, establishing and enhancing interaction with commercial and industry associations, leading China Policy Council to drive policy intelligence and corresponding strategies, and generates health and economic evidence to support product market access and competitive selling. Anita is now a designated delegate for AdvaMed China Executive Committee and leader for Inclusion & Diversity and WIN (Women Initiative Network) in China. Prior to joining BD, Anita served Novartis for 6 years, and her last role is the Head of Communications for Novartis Pharma Greater China, reporting to the Chairman.
Helen Chen
Greater China Managing Partner at L.E.K. Consulting LimitedHelen Chen is a Managing Director of L.E.K. Consulting based in Shanghai. She is the head of the China office and sat on L.E.K.’s Global Leadership Team, the firm’s governing board, from 2012 to 2016. Helen has over 30 years of consulting and industry experience in the U.S. and Asia, and has resided in China since 2000.
Helen is the head of L.E.K.’s China and Asia life sciences practice, with extensive case work and industry experience covering the full biopharmaceutical and medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness. In China, she has developed commercial strategies for international medtechs, investment thesis for financial investors, business plans for domestic startups and policy analyses for industry associations.
Helen produced the 2016 Shanghai government commissioned Chinese outbound investment guide From China to the World: An International Investment and Market Access Guide for Chinese Biopharmaceutical Companies. She is a frequent speaker and author on the opportunities and issues in the China healthcare and life sciences, and has been quoted by publications including BioCentury, BioWorld, In Vivo, Wall Street Journal, Financial Times and Forbes Asia.
Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the U.S. and China. She was an associate director of finance at Genentech and a sales planner at Abbott Laboratories. She is on the organising committee for the Medtronic Sequoia Fund, and was on the Board of Pharmaceutical Management Sciences Association from 1995 to 1997.
Helen received her A.B. cum laude in applied mathematics from Harvard University.
Jarod Xiaojie Liu
Marketing Director of RocheMr. Liu Xiaojie has more than 10 years of experience in the pharmaceutical sector including management consulting, enterprise performance planning, and regional sales and marketing.
Frank Song
Marketing Director of SanofiFrank Song is a Marketing Director at Sanofi. He is an experienced marketer with more than 10 years of experience in the pharmaceutical sector for several MNCs. He has successfully launched new products and revitalized mature products in chronic disease, oncology, and other fields.
Xiaoming Zou, Ph.D.
CEO of EOC Pharma• Over 16 years of experience in pharmaceutical industry;
• Joined Eddingpharm in 2012 as CBO;
• Currently servers as CEO of EOC Pharma;
• Former Executive Director of Licensing at Amgen;
• Former Director of External Research at GSK;
• Ph.D. from Columbia University; B.S. and M.S. from Tsinghua University
Greg Scott
Founder and Chairman of ChinaBio® GroupGreg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on investment and partnering, including the ChinaBio® Partnering Forum which draws nearly 1000 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today: a widely read newsletter covering the China life science industry. He also serves on the board of a medical device and cancer drug company, and formerly the BayHelix Group, a group of (mostly) Chinese life science executives. Headquartered in Shanghai, ChinaBio® has staff in San Diego, Palo Alto, and Basel, Switzerland. Greg lives and works in Shanghai and visits California a few times a year to enjoy the blue skies and sandy beaches.
Tommy Li
Senior Director of Business Development, Greater China at BDTommy Li has been working in the pharmaceutical and medical device industry on business development, strategy, and management positions for 17 years including 7 years at BD Greater China. Tommy is also a member of BD Greater China leadership team. Tommy has been working with corporate and all segmental business development teams on China market opportunity assessment, forecasting models and due diligence for more than ten global business development projects, which have been highly recognized by corporate and segment stakeholders. Tommy also initiated China local business development strategies, projects and has signed six local deals include acquisition, partnership, product supplying, OEM and exclusive distributions in the past seven years. Tommy was in charging of strategic planning and strategic marketing at C.R. Bard which was merged by BD in 2017 as well. On that role, he closely worked with global and local management on building 3-5 year China strategies, investment plan, and execution.
Prior to BD, Tommy was a senior business development manager in China at Merck KGaA, a leading global company in healthcare, life science, and performance materials. Prior to Merck KGaA, Tommy held positions of increasing responsibilities with a top South Korea pharmaceutical company, Hanmi Pharma and Chinese pharmaceutical company, Tasly Group on new product development, market research and business development.
James Lu
Partner at Cooley LLPJames is a partner at Cooley LLP and heads the firm's China Business and Finance Practice. He focuses on China-related corporate and securities transactions in the technology and life science sectors, including foreign direct investment, private equity, and venture capital investments, mergers and acquisitions and public offerings. He also has broad experience advising clients on complex cross-border commercial transactions involving unique structures and contractual arrangements designed to comply with legal requirements in multiple jurisdictions, including licensing, joint venture, manufacturing and distribution arrangements.
James is a frequent speaker at local and international conferences and has spoken extensively on topics relating to China's venture capital and capital market environment.
Prior to joining Cooley, James held various marketing and business development management positions in the life science industry and worked in the United States for organizations including the Eastman Kodak Co., Life Technologies Corp., and several startups. He focused on commercialization and has 10+ years of experience working with scientists and technology transfer professionals to transform ideas into successful products.
Joan (Huaqiong) Shen, MD, Ph.D
Head of Research and Development at I-Mab PharmaJoan obtained her Ph.D. in life sciences and is a licensed physician with board certification in the U.S. She received postdoctoral training in endocrinology, psychopharmacology and clinical pharmacology. Being responsible for global clinical development programs across phase 1-4, she has worked in Eli Lilly & Co, Wyeth and Pfizer while in the U.S., and gained rich experiences working with FDA, EMEA, CFDA, PMDA, and KFDA. Joan was sent by Pfizer in 2011 as the China clinical head. She later joined Hengrui Pharmaceutical as the CMO. In Hengrui, Joan built the largest clinical team among China’s domestic pharmaceuticals and led the successful conduction of clinical trials in China, USA, and Australia. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China development head in 2015 and is responsible for all the development programs, where she led multiple successful NDA approvals by CFDA. During this time, she was elected as the co-chair of RDPAC R&D core team. Joan joined I-Mab biopharma as the head of R&D in 2017. Joan was granted the honor of “Talent of Innovation” by the “National Thousand Talent Program.” She was also elected as the executive committee member of the China New Drug Research Evaluation Committee. She holds academic positions as the guest professor of Beijing University Clinical Research Institute and was the adjunctive professor of Indiana University School of Medicine.
Jonathan Wang
Senior Managing Director and Founding Partner of OrbiMedDr. Jonathan Wang is a founding partner and Senior Managing Director of OrbiMed Asia (OrbiMed is the world’s largest healthcare-dedicated investment firm). He is a HKEX Biotech Advisory Panel member and is a co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders.
Under the supervision of Eric Kandel, a Nobel Laureate, he obtained a Ph.D. in Neurobiology from Columbia University. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University.
He has close to 30 years of healthcare and life sciences experience, spanning investment, entrepreneurship, finance, and research. He has been named one of the top 10 healthcare investors in China (ChinaVenture) and has invested in many successful companies, such as Genewiz, ZAI Lab, ForteBIO and EA.
Shilpi Biswas
Vice President at AmCham ShanghaiShilpi is a Transformation and Global Growth Leader and her roles include executive positions in Product development, P&L management, Global commercialization at General Electric, Unilever, Delphi, General Motors, and SPX . Her 20+ year business career has been focused on growing and diversifying companies in adjacent markets and developing portfolios with innovative ideas, helping to shape concepts into viable products and launching them successfully in the global markets, along with being a change agent during critical transition period in legacy industries (Automotive, Telecom, and Industrials). Transitioning and innovating corporate culture to match the dynamic market requirements and enhancing staff capabilities in a continuous growth mindset to deliver P&L results has been her core competency through out her career. Shilpi has worked and lived in USA, India, Japan, Kenya, Ghana, Mexico and now in China.
Shilpi Biswas joined American Chamber of Commerce in Shanghai, as Vice President, as of May 2017. Shilpi’s previous role was General Manager, Product Management, for GE Lighting, USA. In her role Shilpi was responsible for providing strategic direction and P&L leadership to drive profitable growth and global share across all Consumer Lamp technologies.
Inspiration, Aspiration and Transformation are her core values. She is a Believer that ‘If you can See it, you can Be It”.